New York jury finds that Teva and distributor Anda violated state’s public nuisance law in their marketing and distribution of opioids. Such claims had been rejected by two previous courts and the verdict in this case shows the challenges companies face in ongoing litigation.
The jury verdict against Teva Pharmaceuticals USA Inc. in New York state’s opioid trial shows the significant liability opioid makers face despite victories in the only other two cases that have reached trial decisions and may impact global settlement discussions that have been bogged down for the past two years.
After a six-month trial, a six-member jury issued a verdict on 30 December, finding that Teva and its affiliates and distributor Anda, Inc. caused or contributed to an interference...
Deputy FDA Commissioner Grace Graham acknowledged the importance of user fees, while also calling for restructuring. She also said part of MAHA's mission is to reexamine uses of drugs not supported by data.
At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.
A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.
